First Time Loading...

Bio Rad Laboratories Inc
NYSE:BIO

Watchlist Manager
Bio Rad Laboratories Inc Logo
Bio Rad Laboratories Inc
NYSE:BIO
Watchlist
Price: 294.01 USD 3% Market Closed
Updated: May 15, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Balance Sheet

12.6B
+3%
Assets
Growth Rates:
1 Year
-8%
3 Years
-9%
5 Years
+84%
7 Years
+219%
10 Years
+266%
3.6B
+0%
Liabilities
Growth Rates:
1 Year
-9%
3 Years
+7%
5 Years
+78%
7 Years
+186%
10 Years
+194%
9.1B
+4%
Equity
Growth Rates:
1 Year
-7%
3 Years
-15%
5 Years
+86%
7 Years
+234%
10 Years
+305%

Balance Sheet Decomposition
Bio Rad Laboratories Inc

12.6B
Assets
3.6B
Liabilities
12.6B
Assets
3.6B
Liabilities
Current Assets 3.1B
Cash & Short-Term Investments 1.6B
Receivables 444.8m
Other Current Assets 970.5m
Non-Current Assets 9.5B
Long-Term Investments 8B
PP&E 711.3m
Intangibles 726.4m
Other Non-Current Assets 92.9m
Current Liabilities 466.2m
Accounts Payable 102.8m
Accrued Liabilities 186.5m
Other Current Liabilities 176.9m
Non-Current Liabilities 3.1B
Long-Term Debt 1.2B
Other Non-Current Liabilities 1.9B

Balance Sheet
Bio Rad Laboratories Inc

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
413
458
456
384
432
661
662
471
434
404
Cash Equivalents
413
458
456
384
432
661
662
471
434
404
Short-Term Investments
284
329
383
371
413
454
329
399
1 356
1 203
Total Receivables
378
391
372
465
392
393
419
424
495
489
Accounts Receivables
378
391
372
465
392
393
419
424
495
489
Other Receivables
0
0
0
0
0
0
0
0
0
0
Inventory
471
490
525
595
584
554
622
572
719
781
Other Current Assets
170
109
108
162
202
119
107
125
153
172
Total Current Assets
1 716
1 778
1 845
1 977
2 023
2 180
2 140
1 990
3 158
3 048
PP&E Net
429
438
489
493
509
701
694
716
680
724
PP&E Gross
429
438
489
493
509
701
694
716
680
724
Accumulated Depreciation
660
679
739
812
818
883
961
1 002
1 009
1 067
Intangible Assets
254
214
162
174
133
146
199
254
332
321
Goodwill
500
496
477
506
220
264
292
347
406
414
Long-Term Investments
389
720
831
1 028
2 656
4 638
9 561
14 387
8 831
7 698
Other Long-Term Assets
52
65
48
95
70
80
87
104
95
95
Other Assets
500
496
477
506
220
264
292
347
406
414
Total Assets
3 341
N/A
3 710
+11%
3 851
+4%
4 273
+11%
5 611
+31%
8 009
+43%
12 973
+62%
17 799
+37%
13 502
-24%
12 299
-9%
Liabilities
Accounts Payable
129
122
133
135
122
107
139
142
135
429
Accrued Liabilities
153
158
163
172
144
215
259
313
231
180
Short-Term Debt
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
0
0
0
0
426
2
0
0
0
Other Current Liabilities
164
161
175
195
184
157
231
225
202
197
Total Current Liabilities
447
441
471
503
451
905
632
681
569
523
Long-Term Debt
436
434
434
435
439
14
12
11
1 198
1 199
Deferred Income Tax
155
233
223
222
553
998
2 077
3 065
1 770
1 475
Other Liabilities
119
111
135
183
148
337
372
358
350
361
Total Liabilities
1 156
N/A
1 219
+5%
1 264
+4%
1 343
+6%
1 591
+18%
2 254
+42%
3 093
+37%
4 114
+33%
3 886
-6%
3 558
-8%
Equity
Common Stock
0
0
0
0
0
0
0
0
0
0
Retained Earnings
1 695
1 808
1 836
1 830
3 722
5 471
9 268
13 525
9 898
9 261
Additional Paid In Capital
271
300
333
361
394
410
429
442
447
449
Unrealized Security Profit/Loss
0
369
435
684
3
7
10
6
10
1
Treasury Stock
0
0
0
0
49
38
100
106
264
633
Other Equity
219
13
17
55
50
95
273
181
457
337
Total Equity
2 185
N/A
2 491
+14%
2 587
+4%
2 930
+13%
4 020
+37%
5 755
+43%
9 880
+72%
13 685
+39%
9 615
-30%
8 741
-9%
Total Liabilities & Equity
3 341
N/A
3 710
+11%
3 851
+4%
4 273
+11%
5 611
+31%
8 009
+43%
12 973
+62%
17 799
+37%
13 502
-24%
12 299
-9%
Shares Outstanding
Common Shares Outstanding
29
29
30
30
30
30
30
30
30
29

See Also

Summary
BIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIO stock valuation using valuation multiples.
Wall Street Estimates
BIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 137,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.